Vistin Pharma ASA operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Vistin Pharma ASA with three other
companies in this sector in Norway:
sales of 181.51 million Norwegian Kroner [US$19.78 million]
of which 61%
was Hexvix/Cysview Own Sales),
Biotec Pharmacon ASA
(66.77 million Norwegian Kroner [US$7.28 million]
of which 51%
was Enzymes), and
(101.72 million Norwegian Kroner [US$11.09 million]
of which 100%
was Vitamin K2/MenaQ7).
During the year ended December of 2018, sales at
Vistin Pharma ASA were NOK 198.99 million (US$21.69 million).
increase of 12.6%
versus 2017, when the company's sales were NOK 176.69 million.
Despite this increase, sales are still
below the level achieved in 2016, when Vistin Pharma ASA
reported sales of NOK 394.03 million.